Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue ...

"ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC" was originally created and published by ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

If Credit Suisse’s KOLs are correct about prostate cancer drug Xtandi’s latest clinical trial news, a change could be afoot for rival prostate drug Zytiga, which is sold by Johnson & Johnson’s Janssen ...

Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend off growing competition in the market. The results of the phase 3 PROSPER trial show that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On Thursday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide). The trial demonstrated a statistically ...

Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer Astellas ...

Medivation posted second-quarter numbers on Tuesday, and they offer more evidence why Big Pharma and Big Biotech are stumbling over themselves to snap up the company. The company’s flagship drug, ...

A slew of new prostate cancer drugs offer treatment options for advance prostate cancer patients. But Xtandi could become a solution for early stage too. Today, a number of new prostate cancer drugs ...